US2005038499A1PendingUtilityA1

Methods for coating stents with DNA and expression of recombinant genes from DNA coated stents in vivo

66
Priority: Jun 27, 1997Filed: Sep 22, 2004Published: Feb 17, 2005
Est. expiryJun 27, 2017(expired)· nominal 20-yr term from priority
Inventors:Elizabeth G. NabelGary J. NabelZhi-Yong Yang
A61K 9/0024A61L 2300/416A61K 31/711A61K 48/00A61P 9/00A61K 38/45A61K 38/50A61F 2/82A61L 2300/258A61L 2300/252A61L 31/10A61L 2300/606A61L 31/16
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention describes DNA coated stents and methods of using the same to treat or prevent vascular diseases, such as restenosis.

Claims

exact text as granted — not AI-modified
1 - 20 . Cancelled  
     
     
         21 . A method for expressing therapeutically useful amounts of recombinant genes in vivo, comprising the step of placing an implantable device into the vasculature of a patient, wherein the device comprises a biostable intravascular stent coated with a polymer matrix and DNA encoding a therapeutically useful protein, said DNA being uniformly-dispersed within said matrix.  
     
     
         22 . The method of  claim 21 , wherein the therapeutically useful protein is an antiplatelet agent, anticoagulant agent, antimitotic agent, antioxidant, antimetabolite agent, or anti-inflammatory agent.  
     
     
         23 . The method of  claim 21 , wherein the therapeutically useful protein inhibits the proliferation of cells.  
     
     
         24 . The method of  claim 21 , wherein the therapeutically useful protein is thymidine kinase, p16, p21, p27, p57, retinoblastoma or cytosine deaminase.  
     
     
         25 . The method of  claim 24 , wherein the therapeutically useful protein is thymidine kinase or cytosine deaminase.  
     
     
         26 . A method for treating or preventing a vascular disease, comprising the step of placing an implantable device into the vasculature of a patient, wherein the device comprises a biostable intravascular stent coated with a polymer matrix and DNA encoding a protein therapeutically useful for treating the vascular disease, said DNA being uniformly dispersed within said matrix.  
     
     
         27 . The method of  claim 26 , wherein the therapeutically useful protein is an antiplatelet agent, anticoagulant agent, antimitotic agent, antioxidant, antimetabolite agent, or anti-inflammatory agent.  
     
     
         28 . The method of  claim 26 , wherein the therapeutically useful protein inhibits the proliferation of cells.  
     
     
         29 . The method of  claim 26 , wherein the therapeutically useful protein is thymidine kinase, p16, p21, p27, p57, retinoblastoma or cytosine deaminase.  
     
     
         30 . The method of  claim 26 , wherein the therapeutically useful protein is thymidine kinase or cytosine deaminase.  
     
     
         31 . The method of  claim 26 , wherein the vascular disease is restenosis, atherosclerosis, coronary artery bypass graft stenosis or restenosis, arterio-venous fistula stenosis or restenosis, or peripheral artery stenosis or restenosis.  
     
     
         32 . The method of  claim 21 , wherein the DNA is naked DNA.  
     
     
         33 . The method of  claim 21 , wherein the DNA is incorporated into a vector.  
     
     
         34 . The method of  claim 33 , wherein the vector is selected from the group consisting of shuttle vectors, expression vectors, retroviral vectors, adenoviral vectors, adeno-associated vectors and liposomes.  
     
     
         35 . The method of  claim 21 , wherein the therapeutically useful protein is a fusion protein.  
     
     
         36 . The method of  claim 21 , wherein the DNA comprises a sm22α promoter operatively linked to the DNA encoding the therapeutically useful protein.  
     
     
         37 . The method of  claim 26 , wherein the DNA is naked DNA.  
     
     
         38 . The method of  claim 26 , wherein the DNA is incorporated into a vector.  
     
     
         39 . The method of  claim 38 , wherein the vector is selected from the group consisting of shuttle vectors, expression vectors, retroviral vectors, adenoviral vectors, adeno-associated vectors and liposomes.  
     
     
         40 . The method of  claim 26 , wherein the therapeutically useful protein is a fusion protein.  
     
     
         41 . The method of  claim 26 , wherein the DNA comprises a sm22α promoter operatively linked to the DNA encoding the therapeutically useful protein.  
     
     
         42 . The method of  claim 21 , wherein the polymer matrix is formed from an aqueous suspension of DNA and liquid monomeric matrix.  
     
     
         43 . The method of  claim 21 , wherein the stent is a polymeric or metallic stent.  
     
     
         44 . The method of  claim 21 , wherein the stent is stainless steel.  
     
     
         45 . The method of  claim 21 , wherein the stent is coated with about 50 μg to about 5 mg of DNA.  
     
     
         46 . The method of  claim 21 , wherein the polymer matrix comprises fibrin.  
     
     
         47 . The method of  claim 21 , wherein the stent is a polymeric stent comprising poly(ethylene terephthalate), polyacetal, poly(lactic acid), and poly(ethylene oxide)/poly(butylene terephthalate) copolymer.  
     
     
         48 . The method of  claim 26 , wherein the polymer matrix is formed from an aqueous suspension of DNA and liquid monomeric matrix.  
     
     
         49 . The method of  claim 26 , wherein the stent is a polymeric or metallic stent.  
     
     
         50 . The method of  claim 26 , wherein the stent is stainless steel.  
     
     
         51 . The method of  claim 26 , wherein the stent is coated with about 50 μg to about 5 mg of DNA.  
     
     
         52 . The method of  claim 26 , wherein the polymer matrix comprises fibrin.  
     
     
         53 . The method of  claim 26 , wherein the stent is a polymeric stent comprising poly(ethylene terephthalate), polyacetal, poly(lactic acid), and poly(ethylene oxide)/poly(butylene terephthalate) copolymer.  
     
     
         54 . A method for expressing therapeutically useful amounts of recombinant genes in vivo, comprising the step of placing an implantable device into the vasculature of a patient, wherein the device comprises a biostable intravascular stent coated with a polymer matrix and DNA encoding a therapeutically useful protein, said DNA being in contact with said matrix.  
     
     
         55 . The method of  claim 54 , wherein the therapeutically useful protein inhibits the proliferation of cells.  
     
     
         56 . The method of  claim 54 , wherein the therapeutically useful protein is thymidine kinase, p16, p21, p27, p57, retinoblastoma, protein or cytosine deaminase.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.